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Abstract
Occludin is a component of tight junctions, which are essential structural components of 
the blood–brain barrier. However, occludin is expressed in cells without tight junctions, 
implying additional functions. We determined the expression and localisation of occludin 
in astrocytes in cell culture and in human brain tissue, and sought novel binding partners 
using a proteomic approach. Expression was investigated by immunocytochemistry and 
immunoblotting in the 1321N1 astrocytoma cell line and ScienCell human primary astro-
cytes, and by immunohistochemistry in human autopsy brain tissue. Recombinant N- and 
C- terminal occludin was used to pull- down proteins from 1321N1 cell lysates and 
protein- binding partners identified by mass spectrometry analysis. Occludin was ex-
pressed in both the cytoplasm and nucleus of astrocytes in vitro and in vivo. Mass spec-
trometry identified binding to nuclear and cytoplasmic proteins, particularly those related 
to RNA metabolism and nuclear function. Occludin is expressed in several subcellular 
compartments of brain cell- types that do not form tight junctions and the expression pat-
terns in cell culture reflect those in human brain tissue, indicating they are suitable model 
systems. Proteomic analysis suggests that occludin has novel functions in neuroepithelial 
cells that are unrelated to tight junction formation. Further research will establish the roles 
of these functions in both cellular physiology and in disease states.
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1 |  INTRODUCTION
Tight junctions formed by brain endothelial cells are a key 
component of the blood–brain barrier (BBB), limiting para-
cellular and intramembranous diffusion and giving the cell 
polarity (Chow & Gu, 2015; Zlokovic, 2008). Changes in 
the expression of tight junctions have been associated with 
leakage of the BBB in various acute and chronic neurolog-
ical disorders (Dallasta et al., 1999; Kirk, Plumb, Mirakhur, 
& McQuaid, 2003; Nag, Kapadia, & Stewart, 2011; Popescu 
et al., 2009; Sandoval & Witt, 2008).
Tight junctions are composed of a multi- molecular 
complex of proteins that can be divided into integral mem-
brane proteins and cellular scaffolding proteins (Guillemot, 
Paschoud, Pulimeno, Foglia, & Citi, 2008; Haseloff, 
Dithmer, Winkler, Wolburg, & Blasig, 2015). Occludin is 
a tight junction- associated marvel protein (TAMP), charac-
terised by four transmembrane MARVEL (myelin and lym-
phocyte [MAL] and related proteins for vesicle trafficking 
and membrane link) domains that target it to the cell mem-
brane (Yaffe et al., 2012). Occludin binds zonula occludens 
1 (ZO- 1), a member of the membrane- associated guanylate 
kinase (MAGUK)- like proteins through the hairpin structure 
formed by the SH3- U5- GUK- U6 region, thus establishing a 
link between occludin and the actin cytoskeleton (Fanning 
& Anderson, 2009; Fanning et al., 2007; Guillemot et al., 
2008). Basic structural information for occludin is illustrated 
in Figure S1.
Although the protein components of tight junctions are 
well characterised, our understanding of the molecular struc-
ture and protein interactions of tight junctions is more lim-
ited. Claudins are another tight junction protein, and to date 
24 claudins have been identified in humans. Gene manipu-
lation studies which selectively knockout either occludin or 
claudin(s) have demonstrated quite differing effects on tight 
junction function/integrity. Occludin knockout mice have a 
complex phenotype, with considerable growth retardation 
and alterations in their sexual behaviour but they exhibit no 
morphological abnormalities in their tight junctions and bar-
rier function appears normal (Saitou et al., 2000; Schulzke 
et al., 2005). This contrasts with claudin- deficient mice in 
which barrier function is disturbed; for example claudin- 1 
null mice do not survive post- natally due to a compromised 
epidermal barrier (Furuse et al., 2002) while claudin- 5 defi-
cient mice have a “leaky” BBB which also results in death 
post- natally (Nitta et al., 2003). These findings, along with 
the observation that occludin is expressed by neuroepithelial 
cells that do not possess tight junctions, suggest that the func-
tion of occludin is more complex than previously supposed.
In studies of BBB alterations with Alzheimer- type pathol-
ogy in an ageing human brain cohort, we observed expression 
of occludin and ZO- 1, but not claudin- V in glial cells in white 
matter and cerebral cortex (Simpson et al., 2010; Viggars 
et al., 2011). We have also shown astrocytic expression of 
genes for occludin, ZO- 1 and claudins in a gene expression 
microarray study, with down- regulation of the tight junction 
Kyoto encyclopedia of genes and genomes (KEGG) pathway 
(hsa04530), in addition to other junctional pathways with in-
creasing Braak neurofibrillary tangle stage (Simpson et al., 
2011). Several other studies have also documented expres-
sion of certain tight junction proteins in cultured astrocytes 
and in human tissue (Bauer et al., 1999; Howarth, Hughes, & 
Stevenson, 1992; Romanitan, Popescu, Winblad, Bajenaru, 
& Bogdanovic, 2007). These data suggest that occludin has 
functions in neuroepithelial cells other than its role in tight 
junctions, and that these functions may be perturbed in age-
ing and neurodegeneration.
In this study we demonstrate that occludin is expressed 
in human astrocytes in vitro and in vivo, and is localised to 
the cytoplasm and nucleus, but not to the cell membrane. To 
investigate possible additional functions, we used mass spec-
trometry (MS) to identify candidate binding partners of oc-
cludin in neuroepithelial cells.
2 |  METHODS
2.1 | Cell culture
The 1321N1 human astrocytoma cell line was cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco), 
supplemented with 10% foetal bovine serum (FBS) (Sigma) 
and 1% penicillin/streptomycin (P/S). Human foetal primary 
astrocytes isolated from the cerebral cortex were purchased 
from ScienCell Research Laboratories (Carlsbad, CA, USA) 
and were cultured in ScienCell medium supplemented with 
FBS, P/S and Astrocyte Growth Supplement (all ScienCell 
Research Laboratories). The endothelial cell line, hCMEC/
D3 (Cedarlane, USA) was cultured in EBM- 2 medium sup-
plemented with vascular endothelial growth factor, insulin- 
like growth factor- 1, 0.025% human epidermal growth 
factor, 0.1% human basic fibroblast growth factor, 0.04% hy-
drocortisone, 0.1% ascorbic acid and 2.5% FBS (Lonza) on 
Collagen- type 1 (Sigma, UK) coated plates.
2.2 | Western blotting
Once cells had reached approximately 80% confluency 
they were pelleted and snap frozen in liquid nitrogen. Cell 
lysates were prepared by resuspending in extra strong lysis 
buffer (100 mM Tris- HCl pH 7.5, 75 mM NaCl, 0.5% (w/v) 
SDS, 20 mM sodium deoxycholate, 1% (v/v) Triton X- 100, 
2 mM Na3VO4, 1.25 mM NaF, 10 mM EDTA, Protease 
Inhibitor Cocktail (PIC) and PhosSTOP (both Roche, Basel 
Switzerland). Lysates were then sonicated followed by cen-
trifugation at 17,000 g(av) for 30  min at 4°C. The protein 
concentration of whole cell lysates was measured using 
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a bichionic acid (BCA) protein assay kit (ThermoFisher 
Scientific, Waltham, MA, USA) and samples were standard-
ised to equal protein concentration before being analysed by 
SDS- PAGE. Samples containing 20–30 μg of protein were 
separated on 10% SDS- PAGE gels and electrophorectically 
transferred onto 0.2 μm Hybond- C extra nitrocellulose mem-
branes (Amersham Laboratories). Membranes were blocked 
in 5% (w/v) bovine serum albumin (BSA) diluted in 0.05% 
Tween 20 in PBS for 30 min at room temperature (RT). 
Membranes were subsequently incubated with an occludin 
primary antibody overnight (O/N) at 4°C, (71–1,500, 1:200 
dilution; ThermoFisher Scientific), α- tubulin (ABM40035, 
1:5,000; Abbkine) was used a loading control. Membranes 
were then incubated with HRP- conjugated secondary an-
tibodies (1:5,000 dilution; DAKO) followed by ECL 
(EZ- ECL Biological Industries). Detected proteins were vis-
ualised using a G:Box Chemi- XT CCD Gel imaging system 
(Syngene).
2.3 | Cell fractionation
1321N1 cells were also fractionated to yield cytoplasmic 
and nuclear fractions to confirm the subcellular localisa-
tion of occludin. For the cytoplasmic fraction, cells were 
trypsinised, collected in PBS and pelleted by centrifugation 
at 800 g(av) for 5 min. Cell pellets were quickly washed with 
hypotonic lysis buffer (10 mM HEPES pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM DTT) and lysed in hypotonic 
lysis buffer with 2 mM PMSF (Sigma) and SIGMAFAST 
PIC tablets, EDTA free (Sigma). Lysates were then sub-
jected to differential centrifugation at 4°C (1,500 g(av) for 
3 min, then 3,500 g(av) for 8 min, and then 17,000 g(av) for 
1 min), supernatants were transferred to fresh tubes after 
each centrifugation. Nuclear pellets obtained after centrifu-
gation at 1,500 g(av) for 3 min were lysed in Reporter lysis 
buffer (Promega) for 10 min on ice before centrifugation at 
17,000 g(av) for 5 min at 4°C. Total fractions were collected 
in Reporter lysis buffer containing 2- mM PMSF (Sigma) 
and PIC prior to lysis for 10 min on ice before centrifuga-
tion at 17,000 g, 5 min, 4°C. Equal volumes of total, nuclear 
and cytoplasmic lysates were subjected to western blotting. 
Membranes were probed with antibodies directed against 
both the C- terminal (ThermoFisher Scientific, 71–1,500, 
1:200 dilution) and the N- terminal of occludin (ab167161, 
1:10,000 dilution; Abcam) O/N at 4°C. Fractionation was 
confirmed by western blotting for heat shock protein fam-
ily A 14 (HSPA14) (ab108612, 1:2,000 dilution; HSPA14 
Rabbit Monoclonal; Abcam) which is expressed in the cy-
toplasm where it functions as a component of the ribosome- 
associated complex (Wada, Hamada, & Satoh, 2006) and 
structure specific recognition protein 1 (SSRP1) (609702, 
1:1,000; Biolegend), a nuclear protein which is a component 
of the facilitates chromatin transcription (FACT) complex 
(Belotserkovskaya, Saunders, Lis, & Reinberg, 2004).
2.4 | Immunocytochemistry
Cultured cells were fixed in 4% paraformaldehyde for 10 min 
at 37°C and then permeabilised in 0.3% Triton X- 100 in PBS 
(3 min at RT). After further washing, cells were incubated 
in 3% bovine serum albumin prior to incubating in occludin 
antibody for 2 hrs at RT (71–1,500, 1:50; Thermo Fisher 
Scientific). Cells were subsequently washed in PBS and 
then incubated with the appropriate species of secondary an-
tibody for 2 hrs at RT (1:500 Alexa Fluor conjugated, Life 
Technologies). Cell nuclei were stained with Hoescht 33342 
(5 μg/ml bisbenzimide in PBS). Coverslips were mounted on 
to glass slides using fluorescent mounting medium (DAKO) 
and cells were examined using a Nikon DS- Ri1 Eclipse mi-
croscope (Nikon, Kingston, UK).
2.5 | Immunohistochemistry
Samples of post- mortem human temporal cortex from 
cases with Alzheimer’s disease, mild cognitive impairment 
(MCI) and controls were obtained from the Newcastle 
Brain Tissue Resource (Newcastle and North Tyneside 
REC 1: 08/H0906/136), following approval by their review 
committee. Case details are shown in Tables S1 and S2. 
Immunohistochemistry was performed on formalin fixed 
paraffin embedded tissue sectioned at 9 μM using a stand-
ard avidin biotinylated enzyme complex (ABC) method, 
and the signal visualised with diaminobenzidine (Vector 
Laboratories, Peterborough, UK). Antigen retrieval was 
performed by microwaving for 15 min in EDTA at pH 
8.0 and the occludin antibody was used at a concentra-
tion of 1:100 O/N at 4°C (Rabbit Polyclonal, 71–1,500, 
ThermoFisher Scientific). Negative and isotype controls 
were included to confirm antibody specificity. For dual 
staining experiments, we used a method we have previ-
ously described (Mathur et al., 2015). Briefly, stained sec-
tions were subsequently blocked with 1.5 % normal serum, 
followed by an avidin- biotin block (Vector Laboratories) 
and then incubated with glial fibrillary acidic protein 
(GFAP) primary antibody diluted 1:500 for 1 hr at RT 
(Rabbit polyclonal, Z0334; DAKO). After incubating in bi-
otinylated secondary antibody (Vectastain Elite kit, Vector 
Laboratories), the signal was visualised with alkaline 
phosphatase- conjugated avidin–biotin complex using the 
substrate Vector Red (Vector Laboratories). All sections 
were counterstained with Harris’s Haematoxylin before 
dehydrating, clearing in xylene and mounting with DPX 
(Sigma) mounting media. Images were captured using a 
Nikon DS Ri1 Eclipse.
4 |   MORGAN et Al.
2.6 | Generation of recombinant occludin
pCMV- SPORT6 (4,396 bp) containing an occludin (OCLN) 
cDNA IMAGE clone (Source Bioscience) was hosted in the 
DH10B Escherichia coli (E. coli) strain with ampicillin re-
sistance and NotI/EcoRV cloning sites. Primers (Sigma) 
were designed to amplify the N- (OCLN_N 1- 56) and the 
C- terminal (OCLN_C 271- 522) domains as well as the full 
length occludin sequence (OCLN 1- 522) (Table 1) and occlu-
din sequences amplified by touchdown PCR. Products were 
run on a 2% agarose gel, excised and digested with Nde1 and 
Xho1, then ligated into the pET24b- GB1- 6His vector fol-
lowed by transformation into the DH5α E. coli strain. The 
DNA sequences of all three inserts were verified by Sanger 
sequencing (conducted by Source Bioscience). Plasmids con-
taining OCLN_N 1- 65, OCLN_C 271- 522 and OCLN 1- 522 
DNA sequences were transformed into the BL21- RP E. coli 
strain.
Expressed proteins were purified from bacterial cul-
tures and analysed by SDS- PAGE. Briefly, induced cultures 
were centrifuged, lysed (50 mM Tris, 1M NaCl, 0.5% (v/v) 
Triton- X 100, PIC, pH 8.0), sonicated and then centrifuged 
at 17,000 g(av) (7 min, 4°C). The resulting supernatant was 
added to TALON Metal Affinity Cobalt Beads (Clontech 
Laboratories) and incubated for 1 hr on a rotary wheel at 4°C. 
GB1- tagged protein was then eluted from the beads and west-
ern blots utilising antibodies with epitopes located in either 
the N- or C- terminal domain of occludin were used to con-
firm the size and successful expression of GB1- OCLN_ N and 
GB1- OCLN_C recombinant proteins (Table 2 for antibodies).
2.7 | Pull- down protein- binding assay
Prior to lysis, 1321N1 cells were treated with 5 mM CaCl2 
and 4 μM A23187 calcium ionophore (Sigma) and incubated 
at 37°C for 15 min. Cells were lysed in lysis buffer (150 mM 
NaCl, 25 mM TrisHCl, 1% (v/v) Triton X- 100, 0.05% (w/v) 
SDS, 10 mM NaF, 1 mM NaVO4, PIC [Roche], pH 8.0) and 
incubated on ice for 30 min, then passed through a 25 G 
needle 10× and centrifuged at 17,000 g(av) for 5 min, after 
which the supernatants were combined and the concentra-
tion determined by Bradford assay. Cell lysates were diluted 
to 1 mg/ml for pull- down assays.
GB1- OCLN_N or GB1- OCLN_C was adsorbed onto 
30 μl IgG bead slurry (GE Healthcare). A GB1- 6His con-
trol was also included in each experiment. Beads were then 
washed and 1321N1 cell lysates were added to the beads with 
a small quantity retained for use as an input sample. The bead–
lysate mixture was incubated O/N at 4°C on a rotary wheel. 
Tubes were then centrifuged at 0.5 g(av) for 2 min and the 
supernatant discarded. To elute proteins, beads were washed 
and then boiled at 95°C for 5 min with 2× Laemmli buffer. 
Eluates were analysed by SDS- PAGE, protein bands were vi-
sualised with either Instant Blue coomassie (Expedeon) or a 
SilverXpress® Silver Staining Kit (Thermo Fisher Scientific), 
according to the manufacturer’s instructions. Bands from two 
gels representing the GB- 1 OCLN_N and GB1 OCLN_C 
pull- down assays were prepared for mass spectrometry as 
previously described (Pandey, Andersen, & Mann, 2000).
2.8 | Mass spectrometry – ESI- MS analysis
Mass spectrometry was performed with an AmaZon ion trap 
mass spectrometer (Bruker Daltonics). Mass spectra were ac-
quired with automated precursor ion selection. Datasets were 
converted to Mascot Generic Files using scripts supplied by 
Bruker and searched against the Swiss- Prot database (re-
lease Jan 2016, 550,116 sequences) with Mascot server 2.5.1 
(Matrix Science, London, UK). Search parameters were as 
follows: enzyme; trypsin; fixed modification carbamiodome-
thyl (C) and variable modification oxidation (M); maximum 
missed cleavages = 1. A peptide ion score of ≤15 as a cut- off 
as calculated by Mascot was also used to filter. Proteins were 
identified using a significance threshold P < 0.05. Protein 
identifications were based on a minimum of two unique pep-
tides and a Mascot score ≥ 50 were considered to be sig-
nificant. The false discovery rates were determined using the 






T A B L E  1  Sequences for occludin 
primers
T A B L E  2  Antibodies used to confirm the size and successful expression of GB1- OCLN_ N and GB1- OCLN_C
Epitope location Antibody Species Dilution Supplier Code
N- terminal Occludin Rabbit 1:10,000 Abcam Ab167161
C- terminal Occludin Rabbit 1:500 ThermoFisher Scientific 71–1,500
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3 |  RESULTS
3.1 | Occludin is expressed in human 
astrocytes
Western blotting of human primary astrocytes and 1321N1 cell 
lysates confirmed expression of occludin in these cells, with 
a clear band at 75 kDa as well as additional fainter bands at a 
number of other molecular weights (Figure 1a). The calculated 
molecular weight of occludin is 59 kDa; however the supplier 
states that this antibody recognises a range of higher molecular 
weight species ranging from 65 to 82 kDa due to hyperphos-
phorylation of occludin, as well as recognising isoforms at 53 
and 23 kDa. Both human primary astrocytes and 1321N1 cells 
showed a similar banding pattern except for the higher molecu-
lar weight bands (human primary astrocytes ~90 kDa, 1321N1 
cells ~150 kDa) and the lower molecular weight bands (human 
primary astrocytes ~40 kDa, 1321N1 cells ~37 kDa).
To confirm that the antibody was specifically detect-
ing occludin we pre- adsorbed the occludin antibody 
(Thermofisher 71- 1,500) overnight with recombinant 
human C- terminal occludin (aa 271- 522). Pre- adsorbing 
the antibody decreased the intensity of the 75 kDa, 50 kDa 
and the 37 kDa occludin bands confirming the specificity 
of the antibody (Figure S2).
To investigate localisation of occludin we initially used im-
munocytochemistry, which demonstrated diffuse cytoplasmic 
expression and punctate nuclear staining for occludin in both 
human primary astrocytes and the 1321N1 human astro-
cytoma cell line. This was not accompanied by membrane 
staining (Figure 1b). To further explore occludin localisation, 
1321N1 cells were fractionated into cytoplasmic and nuclear 
fractions for western blot analysis (Figure 2). Antibodies di-
rected against both the C- terminal and N- terminal were used 
to confirm that cytoplasmic and nuclear occludin possessed 
the C- and N- terminal of occludin. Whole cell lysates from an 
endothelial cell line (hCMEC/D3) were included as a positive 
control. Fractionation was confirmed by probing for proteins 
exclusively localised with the nucleus (SSRP1) and the cyto-
plasm (HSPA14). A strong SSRP1 band was detected in the 
whole cell lysate and nuclear fractions, while HSPA14 was 
almost exclusively confined to the whole cell lysate and the 
cytoplasmic fraction. Occludin was present in both the nu-
clear and cytoplasmic fractions with multiple bands detected 
with both antibodies. Both antibodies detected bands at the 
expected predicted molecular weight(s) of occludin; the C- 
terminal antibody detected a band at approximately ~75 kDa 
band (Figure 2a), while the N- terminal antibody detected a 
band of ~65 kDa (Figure 2b), this difference in the molecular 
weight is likely due to the majority of occludin phosphorylation 
sites residing in the C- terminal region (Dorfel & Huber, 2012; 
Raleigh et al., 2011). Additional bands were also detected at 
~52, 40 and 23 kDa, these lower molecular weight bands have 
F I G U R E  1  Occludin expression in human primary astrocytes and the human astrocytoma line 1321N1. (a) Western blotting confirms 
expression of the protein at the expected size as well as additional bands (see main text for description), molecular weight markers are indicated in 
kDa. (b) Immunocytochemistry for occludin (red) demonstrates both cytoplasmic and nuclear expression of the protein. Nuclei are shown in blue 
(Hoescht), scale bar represents 10μm 
a b
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been described previously as structural monomers or degrada-
tion products (Frankowski et al., 2015; McCaffrey et al., 2009). 
There was little difference in the banding pattern in the different 
cellular compartments except for the absence of the lower mo-
lecular weight bands (37–50 kDa) in the nuclear fraction and 
the presence of a faint band at ~120 kDa in the nuclear fraction.
3.2 | In vivo expression in human 
temporal cortex
Expression of occludin was examined in human temporal neo-
cortex from cases with AD, MCI and controls (Figure 3). In 
addition to the expected expression in endothelial cells, occlu-
din was also expressed in the cytoplasm and nuclei of pyrami-
dal neurons (Figure 3a), which can be recognised on the basis 
of morphology. Neuronal cytoplasmic expression extended 
into proximal neurites. Cytoplasmic astrocyte expression was 
also detected (Figure 3b), and there was also expression in 
glial nuclei (Figure 3e). Immunohistochemistry also decorated 
neuritic plaques with a morphology suggesting their localisa-
tion in dystrophic neurites (Figure 3c). One case showed up- 
regulation of expression of occludin around a focus of cortical 
ischaemia (Figure 3d). Expression of occludin was also ob-
served in capillaries, consistent with the role of this protein in 
tight junctions (Figure 3e). Dual- labelling immunohistochem-
istry showed co- localisation of occludin- positive nuclei with 
GFAP- positive cells (Figure 3e), demonstrating the astrocytic 
expression of this tight junction protein in vivo. Occludin- 
GFAP double- positive cells were not seen in all cases and oc-
cludin was not present in all GFAP positive cells.
3.3 | Mass spectrometry
To further explore nuclear and cytoplasmic, non- tight junc-
tion protein functions, binding partners of occludin were 
sought and identified using MS. Since we were unable to 
precipitate occludin from 1321N1 cells using commercial 
anti- occludin antibodies we developed a pull- down assay 
using GB1- 6His recombinant protein and IgG beads. Full 
length, N- terminal and C- terminal recombinant proteins were 
expressed in bacteria with the C- (271- 522) and N- (1- 65) 
terminal peptides used in a pull- down assay on lysates from 
the 1321N1 astrocytoma cell line. Western blots showed that 
the GB1- OCLN_N recombinant protein was recognised by 
its specific antibody and produced a protein band just above 
15 kDa (Figure S3). There were also two lower molecular 
weight bands, which might be truncated forms of occludin. 
Faint bands around 30 kDa were also visible. The GB1- OCL 
N_C recombinant protein was also recognised by its spe-
cific antibody and produced a protein band of approximately 
45 kDa that corresponds with the size of the protein seen in 
panel A. Lower molecular weight bands were also present, 
which again might be truncated forms of occludin. Full- 
length occludin peptide, however, proved difficult to purify 
and was therefore not used in further experiments.
Eluted samples from the pull- downs were analysed 
using SDS- PAGE in conjunction with in gel digestion and 
MS analysis (Figure S4). Due to the high background in 
the GB1 controls lanes MS was performed on both GB1 
and GB1- occludin domains and only occludin- specific hits 
were retained for the analysis. The results from the MS 
analysis identified nine potential binding partners using 
the C- terminal peptide (Table 3) and 41 proteins with the 
N- terminal peptide (Table 4). The full mass spectrometry 
analysis is provided in Tables S3-S5 for GB1- OCLN_C, 
GB1- OCLN_N and GB1- control. Except for actin, none of 
these proteins were identified in the respective GB1 con-
trols suggesting that they were specific interactions with 
the molecular domains. However, the identification of in-
direct binding proteins cannot be discounted and further 
F I G U R E  2  Occludin expression 
in fractionated human 1321N cells. 
Western blotting using an antibody 
directed against the C-terminal of occludin 
(a) and the N-terminal of occludin (b) 
confirms expression at the expected 
molecular weights.  Whole cell lysates 
from the endothelial cell line hCMEC/
D3  were included as a positive control. 
Cell fractionation was confirmed using an 
antibody directed against SSRP1 (nucleus) 
and HSPA14 (cytoplasm). Molecular weight 
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F I G U R E  3  Immunohistochemistry 
for occludin in human autopsy brain.  
(a) Occludin pyramidal neuron staining 
with pyramidal nuclear reactivity indicated 
(arrows), score 2 (Case 14, MCI). 
(b) Cytoplasmic astrocyte expression 
(arrows, Case 21, AD). (c) Occludin 
reactivity around a plaque (arrows, Case 
29, AD). (d) Occludin up-regulation 
around ischaemic focus, inset showing 
up-regulation in astrocytes (Case 15, MCI). 
(e) Occludin immunopositive glial nucleus 
(arrow). Note several adjacent negative 
nuclei. An occludin-labelled capillary is 
also seen (arrowhead) (Case 11, MCI) 
(f) Dual labelling immunohistochemistry 
for occludin (brown) and GFAP (pink). 
Arrows show occludin positive GFAP-
astrocytes 
T A B L E  3  Putative C- terminal domain occludin binding partners
Accession Name Score Mass (Da) Description
OCLN_HUMAN Occludin 1,629 59,505 An integral membrane protein of the TJC
RLA0_HUMAN 60S acidic ribosomal protein P0 202 34,423 A structural component of the ribosome
ACTB_HUMAN Actin, cytoplasmic 1 141 42,052 A component of the cellular cytoskeleton
DDX3X_HUMAN ATP- dependent RNA helicase DDX3X 87 73,597 Involved in many stages of gene expression 
including transcription
PCBP1_HUMAN Poly(rC)- binding protein 1 78 37,987 Single- stranded nucleic acid binding protein
G3P_HUMAN Glyceraldehyde- 3- phosphate 
dehydrogenase
77 36,201 Participates in nuclear events including 
transcription, RNA transport, DNA replica-
tion and apoptosis
LMNA_HUMAN Prelamin- A/C 58 74,380 A component of the nuclear lamina
HORN_HUMAN Hornerin 56 283,140 A component of the epidermal cornified cell 
envelope
ZO1_HUMAN Tight junction protein ZO- 1 56 195,682 A cytoplasmic scaffolding protein of the TJC
Note. These proteins were identified by mass spectrometry analysis from a gel produced by a pull- down protein- binding assay using GB1- OCLN_C. Known occludin 
binding partners are shown in italics.
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T A B L E  4  Putative N- terminal domain occludin binding partners
Accession Name Score Mass (Da) Description
MYH10_HUMAN Myosin- 10 685 229,827 Involved in cytokinesis
H2B1K_HUMAN Histone H2B type 1- K 1,347 13,882 Component of the nucleosome
H32_HUMAN Histone H3.2 468 15,436 Component of the nucleosome
DHX9_HUMAN ATP- dependent RNA 
helicase A
396 142,181 Unwinds duplex DNA and 
RNA
PPIB_HUMAN Peptidyl- prolyl cis- trans 
isomerase B
247 23,785 Facilitates protein folding
SFPQ_HUMAN Splicing factor, proline- and 
glutamine- rich
190 76,216 Binds DNA and RNA and is 
involved in several nuclear 
processes
NONO_HUMAN Non- POU domain- 
containing octamer- binding 
protein
88 54,311 Binds DNA and RNA and is 
involved in several nuclear 
processes
ITCH_HUMAN E3 ubiquitin- protein ligase 
Itchy homologue
186 103,593 An E3 ubiquitin- protein ligase
TOP2A_HUMAN DNA topoisomerase 2- alpha 185 175,017 Enzyme which catalyses the 
breakage and reannealing of 
DNA
TOP2B_HUMAN DNA topoisomerase 2- beta 145 184,122 Enzyme which catalyses the 
breakage and reannealing of 
DNA
SMCA5_HUMAN SWI/SNF- related matrix- 
associated actin- dependent 
regulator of chromatin 
subfamily A member 5
181 122,513 ATP- dependent helicase 
involved in the remodelling of 
nucleosomes
HNRPU_HUMAN Heterogeneous nuclear 
ribonucleoprotein U
152 91,269 Binds to RNA and is specific to 
the nucleus
ROA3_HUMAN Heterogeneous nuclear 
ribonucleoprotein A3
140 39,799 RNA- binding protein possibly 
involved in mRNA nuclear 
export
ML12A_HUMAN Myosin regulatory light 
chain 12A
134 19,839 Involved in cytokinesis
ROA2_HUMAN Heterogeneous nuclear 
ribonucleoproteins A2/B1
133 37,464 RNA- binding protein possibly 
involved in mRNA nuclear 
export
U520_HUMAN U5 small nuclear ribonu-
cleoprotein 200 kDa 
helicase
131 246,006 RNA helicase
NOP56_HUMAN Nucleolar protein 56 119 66,408 Involved in ribosomal subunit 
biogenesis
HNRPL_HUMAN Heterogeneous nuclear 
ribonucleoprotein L
114 64,720 Splicing factor
H14_HUMAN Histone H1.4 112 21,852 Histone
NPM_HUMAN Nucleophosmin 112 32,726 Multi- functional protein 
involved in ribosome 
biogenesis and transport
RS14_HUMAN 40S ribosomal protein S14 96 16,434 Component of the ribosome
NOP58_HUMAN Nucleolar protein 58 95 60,054 Involved in ribosomal subunit 
biogenesis
(Continues)
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investigation would be needed to determine which are the 
direct binding proteins. Although actin was identified in 
the GB1- control there was a large difference in the number 
of peptides identified and overall mascot score, and it has 
previously been identified as an interacting partner, hence 
it was retained. Potential binding partners identified in-
cluded ZO- 1, actin E3 ubiquitin ligases Itch and Nedd4- 2.
4 |  DISCUSSION
We examined the expression of occludin in human astrocytes 
in vitro and in human tissue in vivo. The subcellular locali-
sation pattern, combined with the protein- binding partners 
identified by proteomic analysis, suggest non- tight junction- 
related functions in these neuroepithelial cells. Nuclear and 
cytoplasmic expression was demonstrated in the 1321N1 
astrocytoma cell line. Cell lines such as this are convenient 
to use because of their growth characteristics, and we there-
fore used this line to obtain adequate amounts of protein 
lysates for the binding partner assays. However, this line is 
neoplasm- derived and, so as to ensure that this is not a cell- 
line effect, we also confirmed expression in well character-
ised human primary astrocyte cells (Garwood et al., 2015) 
and in human post- mortem brain tissue.
Previous studies demonstrated expression of occludin in 
rodent derived astrocytes and neurons in culture and human 
foetal cortical astrocytes (Duffy, John, Lee, Brosnan, & 
Spray, 2000), with expression varying with differentiation 
state (Bauer et al., 1999). Expression has also been described 
in neurons, astrocytes and oligodendrocytes in human brain 
(Romanitan et al., 2007).
Accession Name Score Mass (Da) Description
PSIP1_HUMAN PC4 and SFRS1- interacting 
protein
95 60,181 Transcriptional coactivator
DCD_HUMAN Dermcidin 92 11,391 An anti- microbial peptide
NEDD4_HUMAN E3 ubiquitin- protein ligase 
NEDD4
83 150,276 An E3 ubiquitin- protein ligase
RBMX_HUMAN RNA- binding motif protein, 
X chromosome
81 42,306 RNA- binding protein
DDX21_HUMAN Nucleolar RNA helicase 2 79 87,804 RNA helicase
ARPC4_HUMAN Actin- related protein 2/3 
complex subunit 4
72 19,768 An actin- binding component 
which is involved in actin 
polymerisation
RL40_HUMAN Ubiquitin- 60S ribosomal 
protein L40
72 15,004 Component of the ribosome
U5S1_HUMAN 116 kDa U5 small nuclear 
ribonucleoprotein 
component
70 110,336 A component required for 
pre- RNA splicing
RS6_HUMAN 40S ribosomal protein S6 68 28,834 Ribosomal Protein
DHX15_HUMAN Putative pre- mRNA- splicing 
factor ATP- dependent 
RNA helicase DHX15
66 91,673 A factor involved in pre- 
mRNA processing
H2AY_HUMAN Core histone macro- H2A.1 66 39,764 Histone
RS25_HUMAN 40S ribosomal protein S25 65 13,791 Ribosomal Protein
ILF2_HUMAN Interleukin enhancer- binding 
factor 2
63 43,263 Appears to interact with ILF3 
and may regulate IL2 gene 
transcription
HNRPD_HUMAN Heterogeneous nuclear 
ribonucleoprotein D0
59 38,581 RNA- binding protein
NCBP1_HUMAN Nuclear cap- binding protein 
subunit 1
56 92,864 A component in complexes 
involved in RNA processing
ELAV1_HUMAN ELAV- like protein 1 55 36,240 RNA- binding protein
RS18_HUMAN 40S ribosomal protein S18 50 17,708 Ribosomal Protein
Note. Proteins identified by mass spectrometry analysis from a gel produced by a pull- down protein- binding assay conducted using GB1- OCLN_N. Known occludin 
binding partners are shown in italics.
T A B L E  4  (Continued)
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Here, nuclear expression of occludin was a consistent fea-
ture both in vitro and in vivo. Although non- tight junction 
functions have previously been described for the ZO- proteins, 
suggesting that, as a group, these proteins have other import-
ant cellular roles, there is less evidence relating to potential 
non- tight junction roles of occludin. Aside from its role as a 
tight junction protein occludin regulates centrosome separa-
tion and mitotic entry in Madin- Darby canine kidney cells 
(MDCK) (Runkle, Sundstrom, Runkle, Liu, & Antonetti, 
2011), and recently a novel role for occludin in the regulation 
of retinal endothelial proliferation and angiogenesis has been 
described (Liu et al., 2016). As well as bands in the expected 
molecular weight range for occludin additional smaller mo-
lecular weight bands were detected. These lower molecular 
weight occludin “isoforms” have been described previously 
in endothelial cells (Frankowski et al., 2015; McCaffrey 
et al., 2009) and are detected by multiple occludin antibodies 
(McCaffrey et al., 2007). It is not known if these smaller iso-
forms of occludin have any functional significance.
Similar patterns of expression were observed in neuroep-
ithelial cells in human post- mortem tissue, demonstrating 
that these subcellular localisations are not artefacts of cell 
culture. As our aim here was to demonstrate that cell cul-
ture patterns were good models of the in vivo state, we did 
not quantify variation in expression in the human tissue, but 
there is evidence that non- tight junction expression may vary 
with disease state. Several studies have found that occludin 
and certain claudins are increased in Alzheimer’s disease and 
vascular dementia (Romanitan et al., 2007, 2010; Spulber, 
Bogdanovic, Romanitan, Bajenaru, & Popescu, 2012). In 
contrast, using microarrays coupled with laser- capture micro-
dissection, we previously found a decline in RNA expression 
for occludin specifically in astrocytes with Alzheimer’s neu-
ropathology progression (Simpson et al., 2011). However, 
protein expression may not parallel that of mRNA. It is possi-
ble that other pathological factors, such as oxidative damage 
may contribute to the variation in expression of these pro-
teins, and pathological factors driving alteration of these pro-
teins remain to be fully defined. An interesting observation in 
one case in the current study was up- regulation of occludin 
around an incidental area of infarction. This observation may 
suggest that expression is altered in response to ischaemia/
infarction and is worth further investigation. Expression in 
the neuritic processes around plaques was a notable feature.
To further define possible functions of occludin in as-
trocytes, we undertook a proteomic analysis using MS. We 
were unable to precipitate occludin directly from 1321N1 or 
ScienCell astrocytes. We therefore used recombinant N- and 
C- terminal occludin peptides to pull- down putative binding 
partners. MS has been previously used to identify proteins in 
tight junction complexes in MDCK- II cells (Fredriksson et al., 
2015). We have now used this method to identify binding pro-
teins in non- tight junction bearing cells. Nine binding partners 
were identified with the C- terminal peptide, and 41 with the 
N- terminal. These included proteins that have previously been 
shown to bind to occludin. Both ZO- 1 and actin, which were 
identified in the GB1- OCLN_C pull- down protein- binding 
assay, are known to interact with occludin at the C- terminal 
domain (Li, Fanning, Anderson, & Lavie, 2005; Wittchen, 
Haskins, & Stevenson, 1999). Similarly the E3 ubiquitin li-
gases Itch and Nedd4- 2, which have previously been shown 
to interact with occludin at the N- terminal domain (Raikwar, 
Vandewalle, & Thomas, 2010; Traweger et al., 2002), were 
identified as occludin binding partners in the GB1- OCLN_N 
pull- down protein- binding assay. Thus, our method was able 
to identify previously known binding partners.
Existing literature suggests binding of proteins that are 
associated with nuclear and cytoplasmic functions. ELL ho-
mology in the C- terminus suggests transcriptional processes, 
and interactions with epsin- 1, and dynamin have been de-
scribed (Li et al., 2005; Liu et al., 2010; Murakami, Felinski, 
& Antonetti, 2009). The binding partners identified in the 
present proteomic study suggest novel functions particularly 
in RNA metabolism and in nuclear functions.
DEAD- box helicase 3, X- linked (DDX3X) was iden-
tified as a binding partner. DDX3X is a 662 amino acid, 
73 kDa nucleocytoplasmic ATP- dependent RNA helicase 
(Jankowsky, 2011). DEAD- box helicases bind to RNA 
and ATP through motifs located in the helicase core do-
main and are involved in RNA metabolism (Putnam & 
Jankowsky, 2013). DDX3X interacts with a nuclear export 
protein and component of the mRNP complex known as 
tip- associated protein (TAP) (Guzik et al., 2001; Lai, Lee, 
& Tarn, 2008). DDX3X also directly interacts with mRNA 
and there is also evidence to suggest that DDX3X is in-
volved in translation initiation and the functional assembly 
of 80S ribosomes (Geissler, Golbik, & Behrens, 2012; Lai 
et al., 2008). Interaction with DDX3X and other binding 
proteins therefore suggests that occludin may have roles in 
RNA metabolism.
Several heterogeneous nuclear ribonucleoproteins 
(hnRNPs) were also identified as putative occludin N- 
terminal domain binding partners. These proteins inter-
act with pre- mRNAs and function as components of RNP 
complexes facilitating RNA metabolic processes includ-
ing mRNA export (Geuens, Bouhy, & Timmerman, 2016). 
hnRNP A2/B1 and hnRNPA3 were identified as binding 
partners. These proteins contain a nuclear transport signal 
(M9 motif) (Bogerd et al., 1999; Ma et al., 2002; Michael, 
Choi, & Dreyfuss, 1995), suggesting a role in the trans-
location of occludin between the nucleus and cytoplasm 
in astrocytes. Further analysis was performed using the 
Search Tool for the Retrieval of Interating Genes/Proteins 
(STRING) to identify if any of the proteins identified 
through the MS were predicted to interact. Only ELAVL1, 
an RNA- binding protein that binds to the 3′- UTR region 
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of mRNAs to increase their stability, was present in both 
the MS and the STRING analysis. However this lack of 
overlap is perhaps not unsurprising as STRING predicts 
associations based on current literature as well as compu-
tational prediction methods, and almost all of the research 
to date on occludin has been focused on its role in tight 
junctions.
In conclusion, our data strongly suggest occludin has 
important non- tight junction- related roles in neuroepi-
thelial cells in vivo. Candidate protein- binding partners 
identified in this study suggest that these functions may 
relate to RNA metabolism and nuclear functions, pro-
cesses that are altered in a variety of human neurodegen-
erative disorders. Defining the role of alterations in the 
expression of occludin and its interactions with proteins 
in these key metabolic pathways is therefore an important 
question for future studies of neuroglial cell function and 
neurodegeneration.
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